Do analysts prefer PFSA or RBOT?

Vicarious Surgical has a consensus target price of $7.00, suggesting a potential upside of 1,205.00%. Given Vicarious Surgical's stronger consensus rating and higher possible upside, analysts plainly believe Vicarious Surgical is more favorable than Profusa. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Profusa 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Vicarious Surgical 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Is PFSA or RBOT more profitable?

Profusa's return on equity of 0.00% beat Vicarious Surgical's return on equity. Company Net Margins Return on Equity Return on Assets Profusa N/A N/A -1,348.07% Vicarious Surgical N/A -184.13% -112.50%

Do analysts recommend PFSA or NDRA?

ENDRA Life Sciences has a consensus target price of $25.00, suggesting a potential upside of 491.02%. Given ENDRA Life Sciences' stronger consensus rating and higher probable upside, analysts clearly believe ENDRA Life Sciences is more favorable than Profusa. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Profusa 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 ENDRA Life Sciences 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is PFSA or NDRA more profitable?

Profusa's return on equity of 0.00% beat ENDRA Life Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Profusa N/A N/A -1,348.07% ENDRA Life Sciences N/A -433.64% -204.58%

Do analysts rate PFSA or LUCY?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Profusa 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Innovative Eyewear 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Do analysts prefer PFSA or INBS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Profusa 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Intelligent Bio Solutions 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend PFSA or HSCS?

HeartSciences has a consensus price target of $8.00, suggesting a potential upside of 312.37%. Given HeartSciences' stronger consensus rating and higher probable upside, analysts plainly believe HeartSciences is more favorable than Profusa. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Profusa 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 HeartSciences 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is PFSA or HSCS more profitable?

Profusa's return on equity of 0.00% beat HeartSciences' return on equity. Company Net Margins Return on Equity Return on Assets Profusa N/A N/A -1,348.07% HeartSciences N/A -333.50% -140.18%

Profusa (PFSA) Competitors

$0.27 -0.02 (-7.80%)

Closing price 06/5/2026 04:00 PM Eastern

Extended Trading

$0.28 +0.01 (+5.11%)

As of 06/5/2026 07:59 PM Eastern

Compare

PFSA vs. RBOT, NDRA, LUCY, INBS, and HSCS

Should you buy Profusa stock or one of its competitors? MarketBeat compares Profusa with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Profusa include Vicarious Surgical (RBOT), ENDRA Life Sciences (NDRA), Innovative Eyewear (LUCY), Intelligent Bio Solutions (INBS), and HeartSciences (HSCS). These companies are all part of the "medical equipment" industry.

How does Profusa compare to Vicarious Surgical?

Profusa (NASDAQ:PFSA) and Vicarious Surgical (NYSE:RBOT) are both small-cap medical equipment companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, institutional ownership, media sentiment and valuation.

Profusa has a beta of 0.35, meaning that its share price is 65% less volatile than the broader market. Comparatively, Vicarious Surgical has a beta of 1.76, meaning that its share price is 76% more volatile than the broader market.

9.8% of Profusa shares are owned by institutional investors. Comparatively, 47.3% of Vicarious Surgical shares are owned by institutional investors. 0.8% of Profusa shares are owned by insiders. Comparatively, 9.5% of Vicarious Surgical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Vicarious Surgical had 2 more articles in the media than Profusa. MarketBeat recorded 2 mentions for Vicarious Surgical and 0 mentions for Profusa. Profusa's average media sentiment score of 0.00 equaled Vicarious Surgical'saverage media sentiment score.

Company	Overall Sentiment
Profusa	Neutral
Vicarious Surgical	Neutral

Profusa has higher revenue and earnings than Vicarious Surgical. Vicarious Surgical is trading at a lower price-to-earnings ratio than Profusa, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Profusa	$100K	12.50	-$35.82M	-$169.72	N/A
Vicarious Surgical	N/A	N/A	-$63.22M	-$6.69	N/A

Vicarious Surgical has a consensus target price of $7.00, suggesting a potential upside of 1,205.00%. Given Vicarious Surgical's stronger consensus rating and higher possible upside, analysts plainly believe Vicarious Surgical is more favorable than Profusa.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Profusa	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Vicarious Surgical	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Profusa's return on equity of 0.00% beat Vicarious Surgical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Profusa	N/A	N/A	-1,348.07%
Vicarious Surgical	N/A	-184.13%	-112.50%

Summary

Vicarious Surgical beats Profusa on 8 of the 12 factors compared between the two stocks.

How does Profusa compare to ENDRA Life Sciences?

Profusa (NASDAQ:PFSA) and ENDRA Life Sciences (NASDAQ:NDRA) are both small-cap medical equipment companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, institutional ownership, analyst recommendations and risk.

ENDRA Life Sciences has lower revenue, but higher earnings than Profusa. ENDRA Life Sciences is trading at a lower price-to-earnings ratio than Profusa, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Profusa	$100K	12.50	-$35.82M	-$169.72	N/A
ENDRA Life Sciences	N/A	N/A	-$7.03M	-$8.15	N/A

9.8% of Profusa shares are held by institutional investors. Comparatively, 1.2% of ENDRA Life Sciences shares are held by institutional investors. 0.8% of Profusa shares are held by insiders. Comparatively, 10.0% of ENDRA Life Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profusa's return on equity of 0.00% beat ENDRA Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Profusa	N/A	N/A	-1,348.07%
ENDRA Life Sciences	N/A	-433.64%	-204.58%

Profusa has a beta of 0.35, indicating that its share price is 65% less volatile than the broader market. Comparatively, ENDRA Life Sciences has a beta of -0.04, indicating that its share price is 104% less volatile than the broader market.

ENDRA Life Sciences has a consensus target price of $25.00, suggesting a potential upside of 491.02%. Given ENDRA Life Sciences' stronger consensus rating and higher probable upside, analysts clearly believe ENDRA Life Sciences is more favorable than Profusa.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Profusa	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ENDRA Life Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, ENDRA Life Sciences had 10 more articles in the media than Profusa. MarketBeat recorded 10 mentions for ENDRA Life Sciences and 0 mentions for Profusa. ENDRA Life Sciences' average media sentiment score of 0.80 beat Profusa's score of 0.00 indicating that ENDRA Life Sciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Profusa	Neutral
ENDRA Life Sciences	Positive

Summary

ENDRA Life Sciences beats Profusa on 9 of the 14 factors compared between the two stocks.

How does Profusa compare to Innovative Eyewear?

Profusa (NASDAQ:PFSA) and Innovative Eyewear (NASDAQ:LUCY) are both small-cap medical equipment companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, profitability, risk, earnings and dividends.

Profusa has a beta of 0.35, suggesting that its stock price is 65% less volatile than the broader market. Comparatively, Innovative Eyewear has a beta of 2.66, suggesting that its stock price is 166% more volatile than the broader market.

9.8% of Profusa shares are owned by institutional investors. Comparatively, 1.0% of Innovative Eyewear shares are owned by institutional investors. 0.8% of Profusa shares are owned by insiders. Comparatively, 1.7% of Innovative Eyewear shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Innovative Eyewear has higher revenue and earnings than Profusa. Innovative Eyewear is trading at a lower price-to-earnings ratio than Profusa, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Profusa	$100K	12.50	-$35.82M	-$169.72	N/A
Innovative Eyewear	$2.66M	2.18	-$7.59M	-$1.69	N/A

Profusa has a net margin of 0.00% compared to Innovative Eyewear's net margin of -272.42%. Profusa's return on equity of 0.00% beat Innovative Eyewear's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Profusa	N/A	N/A	-1,348.07%
Innovative Eyewear	-272.42%	-83.37%	-76.02%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Profusa	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Innovative Eyewear	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

In the previous week, Innovative Eyewear had 2 more articles in the media than Profusa. MarketBeat recorded 2 mentions for Innovative Eyewear and 0 mentions for Profusa. Profusa's average media sentiment score of 0.00 beat Innovative Eyewear's score of -1.00 indicating that Profusa is being referred to more favorably in the media.

Company	Overall Sentiment
Profusa	Neutral
Innovative Eyewear	Negative

Summary

Innovative Eyewear beats Profusa on 8 of the 14 factors compared between the two stocks.

How does Profusa compare to Intelligent Bio Solutions?

Profusa (NASDAQ:PFSA) and Intelligent Bio Solutions (NASDAQ:INBS) are both small-cap medical equipment companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, profitability, analyst recommendations, media sentiment and institutional ownership.

Intelligent Bio Solutions has higher revenue and earnings than Profusa. Intelligent Bio Solutions is trading at a lower price-to-earnings ratio than Profusa, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Profusa	$100K	12.50	-$35.82M	-$169.72	N/A
Intelligent Bio Solutions	$3.05M	1.92	-$10.57M	-$12.22	N/A

In the previous week, Intelligent Bio Solutions had 2 more articles in the media than Profusa. MarketBeat recorded 2 mentions for Intelligent Bio Solutions and 0 mentions for Profusa. Profusa's average media sentiment score of 0.00 equaled Intelligent Bio Solutions'average media sentiment score.

Company	Overall Sentiment
Profusa	Neutral
Intelligent Bio Solutions	Neutral

9.8% of Profusa shares are owned by institutional investors. Comparatively, 33.0% of Intelligent Bio Solutions shares are owned by institutional investors. 0.8% of Profusa shares are owned by insiders. Comparatively, 1.3% of Intelligent Bio Solutions shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Profusa	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Intelligent Bio Solutions	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Profusa has a beta of 0.35, meaning that its share price is 65% less volatile than the broader market. Comparatively, Intelligent Bio Solutions has a beta of 4.21, meaning that its share price is 321% more volatile than the broader market.

Profusa has a net margin of 0.00% compared to Intelligent Bio Solutions' net margin of -296.73%. Profusa's return on equity of 0.00% beat Intelligent Bio Solutions' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Profusa	N/A	N/A	-1,348.07%
Intelligent Bio Solutions	-296.73%	-176.09%	-89.71%

Summary

Intelligent Bio Solutions beats Profusa on 8 of the 12 factors compared between the two stocks.

How does Profusa compare to HeartSciences?

Profusa (NASDAQ:PFSA) and HeartSciences (NASDAQ:HSCS) are both small-cap medical equipment companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, media sentiment, analyst recommendations and profitability.

HeartSciences has a consensus price target of $8.00, suggesting a potential upside of 312.37%. Given HeartSciences' stronger consensus rating and higher probable upside, analysts plainly believe HeartSciences is more favorable than Profusa.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Profusa	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
HeartSciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Profusa's return on equity of 0.00% beat HeartSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Profusa	N/A	N/A	-1,348.07%
HeartSciences	N/A	-333.50%	-140.18%

Profusa has a beta of 0.35, indicating that its share price is 65% less volatile than the broader market. Comparatively, HeartSciences has a beta of 1.96, indicating that its share price is 96% more volatile than the broader market.

In the previous week, HeartSciences had 2 more articles in the media than Profusa. MarketBeat recorded 2 mentions for HeartSciences and 0 mentions for Profusa. Profusa's average media sentiment score of 0.00 equaled HeartSciences'average media sentiment score.

Company	Overall Sentiment
Profusa	Neutral
HeartSciences	Neutral

9.8% of Profusa shares are held by institutional investors. Comparatively, 17.2% of HeartSciences shares are held by institutional investors. 0.8% of Profusa shares are held by insiders. Comparatively, 4.9% of HeartSciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

HeartSciences has lower revenue, but higher earnings than Profusa. HeartSciences is trading at a lower price-to-earnings ratio than Profusa, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Profusa	$100K	12.50	-$35.82M	-$169.72	N/A
HeartSciences	N/A	N/A	-$8.77M	-$4.94	N/A

Summary

HeartSciences beats Profusa on 10 of the 13 factors compared between the two stocks.

Get Profusa News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PFSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PFSA vs. The Competition

Export

Metric	Profusa	Surgical, Medical, And Dental Instruments And Supplies Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$1.25M	$2.57B	$4.83B	$11.99B
Dividend Yield	N/A	N/A	9.65%	5.55%
P/E Ratio	0.00	2.00	21.69	23.62
Price / Sales	12.50	367.14	174.39	112.45
Price / Cash	N/A	7.68	46.39	54.60
Price / Book	-0.01	5.79	27.92	6.35
Net Income	-$35.82M	-$69.38M	$109.80M	$337.59M
7 Day Performance	-24.29%	-3.88%	0.56%	-2.51%
1 Month Performance	-44.83%	-4.72%	0.07%	-0.69%
1 Year Performance	N/A	40.12%	12.30%	25.37%

Profusa Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PFSA Profusa	0.178 of 5 stars	$0.27 -7.8%	N/A	N/A	$1.25M	$100K	N/A	2
RBOT Vicarious Surgical	1.5826 of 5 stars	$0.96 flat	$7.00 +629.2%	-93.1%	$6.84M	N/A	N/A	210	News Coverage
NDRA ENDRA Life Sciences	3.3816 of 5 stars	$5.36 +3.1%	$30.00 +459.7%	+25.1%	$6.60M	N/A	N/A	20	Analyst Revision Gap Down High Trading Volume
LUCY Innovative Eyewear	0.6533 of 5 stars	$1.02 flat	N/A	-66.4%	$6.53M	$2.66M	N/A	9	News Coverage Analyst Downgrade
INBS Intelligent Bio Solutions	0.1947 of 5 stars	$2.49 -6.0%	N/A	-84.4%	$6.34M	$3.05M	N/A	10	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PFSA) was last updated on 6/6/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Profusa (PFSA) Competitors

PFSA vs. RBOT, NDRA, LUCY, INBS, and HSCS

How does Profusa compare to Vicarious Surgical?

Summary

How does Profusa compare to ENDRA Life Sciences?

Summary

How does Profusa compare to Innovative Eyewear?

Summary

How does Profusa compare to Intelligent Bio Solutions?

Summary

How does Profusa compare to HeartSciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PFSA vs. The Competition

Profusa Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Profusa (PFSA) Competitors

PFSA vs. RBOT, NDRA, LUCY, INBS, and HSCS

How does Profusa compare to Vicarious Surgical?

Which has more volatility and risk, PFSA or RBOT?

Do institutionals & insiders hold more shares of PFSA or RBOT?

Does the media refer more to PFSA or RBOT?

Which has better valuation and earnings, PFSA or RBOT?

Do analysts prefer PFSA or RBOT?

Is PFSA or RBOT more profitable?

Summary

How does Profusa compare to ENDRA Life Sciences?

Which has higher valuation and earnings, PFSA or NDRA?

Do insiders and institutionals hold more shares of PFSA or NDRA?

Is PFSA or NDRA more profitable?

Which has more risk & volatility, PFSA or NDRA?

Do analysts recommend PFSA or NDRA?

Does the media refer more to PFSA or NDRA?

Summary

How does Profusa compare to Innovative Eyewear?

Which has more risk & volatility, PFSA or LUCY?

Do insiders & institutionals believe in PFSA or LUCY?

Which has preferable earnings & valuation, PFSA or LUCY?

Is PFSA or LUCY more profitable?

Do analysts rate PFSA or LUCY?

Does the media favor PFSA or LUCY?

Summary

How does Profusa compare to Intelligent Bio Solutions?

Which has preferable earnings & valuation, PFSA or INBS?

Does the media favor PFSA or INBS?

Do institutionals and insiders have more ownership in PFSA or INBS?

Do analysts prefer PFSA or INBS?

Which has more volatility and risk, PFSA or INBS?

Is PFSA or INBS more profitable?

Summary

How does Profusa compare to HeartSciences?

Do analysts recommend PFSA or HSCS?

Is PFSA or HSCS more profitable?

Which has more volatility & risk, PFSA or HSCS?

Does the media favor PFSA or HSCS?

Do insiders and institutionals hold more shares of PFSA or HSCS?

Which has stronger earnings and valuation, PFSA or HSCS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PFSA vs. The Competition

Profusa Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools